

CONFERENCE COMMITTEE REPORT

MR. PRESIDENT and MR. SPEAKER: Your committee on conference on House amendments to **SB 250** submits the following report:

The Senate accedes to all House amendments to the bill, and your committee on conference further agrees to amend the bill as printed with House Committee amendments, as follows:

On page 1, in line 9, after "(1)" by inserting "'Biospecimen" means biological materials obtained from living or deceased human subjects.

(2)";

On page 2, in line 39, after "(b) (1)" by inserting "If a patient's biospecimen is used or requested for use by an eligible facility for a purpose other than the individualized investigative treatment of such patient, the patient or the patient's estate shall be notified of the intended use and asked to consent to such intended use of such biospecimen.

(2) Prior to a profit being realized on any product developed from a patient's biospecimen, an eligible facility shall disclose to the patient or the patient's estate each potential commercial application. The patient or the patient's estate must consent to each commercial application of the patient's biospecimen, which shall include a profit-sharing agreement or other contractual obligations benefiting the patient or such patient's estate for the commercial application of such patient's biospecimen.

(c) (1)";

And by redesignating subsections, paragraphs, subparagraphs and clauses accordingly;

And your committee on conference recommends the adoption of this report.

Conferees on part of House

Conferees on part of Senate